holx

The company expects the deal to add $0.20 per share to adjusted EPS in its first year after the closing of the deal.

Hologic expects to fund the deal through cash, and added term loans.

Hologic (NASDAQ:HOLX) announced its acquisition of Gen-Probe (NASDAQ:GPRO) in a cash deal valued at $82.75 a share, which represents a 20% premium over the company's Friday close.

Makena, previously called Gestiva, has faced years of delays at the FDA, which issued an "approvable" letter for the drug in October 2006, but delayed further action in January 2009. The agency requested more information on the dr

Hologic (HOLX) is down fractionally in choppy trade around the even mark, after announcing today that its drug, Makena, designed to prevent premature birth, was approved by the U.S. Food and Drug Administration, but it added that

Per the terms of an asset purchase agreement between Hologic (HOLX) and KV Pharmaceutical (KV.A. KV.B), Hologic will transfer the company's Makena assets to KV upon the satisfaction of certain conditions, including receipt of a $1

K-V Pharmaceutical (KV.A) exploded on a wave of heavy volume that sent shares up`48% in morning trading, after the US Food and Drug Administration approved its drug Makena, which reduces the risk of preterm births in pregnant wome

Shares of Hologic are currently trading 0.7% lower to $19.25. The company is scheduled to report earnings on Jan 31.

Citigroup is upgrades shares of Hologic (NASDAQ:HOLX) from "Hold" to "Buy" citing the pending approval of its 3F mammography technology which may serve to be a catalyst for the stock. The firm believes the new technology could dri